Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Accumulated Expenses (2022 - 2025)

Mainz Biomed's Accumulated Expenses history spans 3 years, with the latest figure at $822917.0 for Q4 2024.

  • For Q4 2024, Accumulated Expenses rose 13.47% year-over-year to $822917.0; the TTM value through Dec 2024 reached $822917.0, up 13.47%, while the annual FY2024 figure was $822917.0, 13.47% up from the prior year.
  • Accumulated Expenses for Q4 2024 was $822917.0 at Mainz Biomed, up from $725208.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.0 million in Q4 2022 and bottomed at $725208.0 in Q4 2023.
  • The 3-year median for Accumulated Expenses is $822917.0 (2024), against an average of $861885.7.
  • The largest annual shift saw Accumulated Expenses crashed 30.1% in 2023 before it increased 13.47% in 2024.
  • A 3-year view of Accumulated Expenses shows it stood at $1.0 million in 2022, then plummeted by 30.1% to $725208.0 in 2023, then grew by 13.47% to $822917.0 in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Accumulated Expenses are $822917.0 (Q4 2024), $725208.0 (Q4 2023), and $1.0 million (Q4 2022).